WO1997048419A1 - Gene therapy for obesity - Google Patents
Gene therapy for obesity Download PDFInfo
- Publication number
- WO1997048419A1 WO1997048419A1 PCT/US1997/012131 US9712131W WO9748419A1 WO 1997048419 A1 WO1997048419 A1 WO 1997048419A1 US 9712131 W US9712131 W US 9712131W WO 9748419 A1 WO9748419 A1 WO 9748419A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- leptin
- gene
- vector
- mammal
- mice
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- Figure 8 shows glucose levels of the mice treated with either recombinant leptin, reporter gene or adenovirus containing the leptin gene.
- One vector which is suitable for transient expression of the ob gene is an adenovirus which has a deletion in the El gene.
- Such vectors are known, as taught in the aforementioned WO 95/00655 and Mitani et al., 1995 publications. These viruses preferentially infect hepatocytes, where they persist for approximately 3-4 weeks after the initial infection. While in the hepatocytes, these viruses can express the heterologous gene.
- Animals which transiently express the ob or u/b-receptor gene products are valuable research tools. For example, they can be used to monitor the effects of decreasing amounts of leptin, or the effect of various exogenously supplied substances (such as hormones or putative leptin receptor agonists and antagonists) in an environment of decreasing leptin availability.
- mice which are obese have been injected with an adenovirus containing the human leptin gene, although the leptin gene from any desired species may be used, and in preferred embodiments, the gene which is from the same species as the host is used.
- mice which are obese have been injected with an adenovirus containing the human leptin gene, although the leptin gene from any desired species may be used, and in preferred embodiments, the gene which is from the same species as the host is used.
- mice were housed 5 per cage and fed milled Purina Chow 5008 in feed cups with lids. 24 hour food consumption was measured at the same time each day. Only after food consumption was equilibrated to a fairly constant level, usually 20-25 grams chow/5 mice-day, was virus injected. On the day of injection but before injection, food consumption, body weight, and a baseline blood sample were taken in the morning from a snipped end of tail. Blood was collected into heparinized capillary tube (total volume approximately 70- 100 ⁇ l). Hematocrit was measured, and plasma was collected.
- Group 2 received 2.75 x 10 s / gm wt of AdHCMV- ⁇ gal reporter
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97932580A EP0921820A4 (en) | 1996-06-20 | 1997-06-20 | Gene therapy for obesity |
JP10503629A JP2000514422A (en) | 1996-06-20 | 1997-06-20 | Gene therapy for obesity |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2081296P | 1996-06-20 | 1996-06-20 | |
US60/020,812 | 1996-06-20 | ||
GBGB9615787.0A GB9615787D0 (en) | 1996-07-26 | 1996-07-26 | Gene therapy for obesity |
GB9615787.0 | 1996-07-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997048419A1 true WO1997048419A1 (en) | 1997-12-24 |
Family
ID=26309766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/012131 WO1997048419A1 (en) | 1996-06-20 | 1997-06-20 | Gene therapy for obesity |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0921820A4 (en) |
JP (1) | JP2000514422A (en) |
CA (1) | CA2258504A1 (en) |
WO (1) | WO1997048419A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000011173A1 (en) * | 1998-08-21 | 2000-03-02 | Albany Medical College | Leptin-related peptides |
JP2002521496A (en) * | 1998-07-28 | 2002-07-16 | フラームス・インテルウニフェルシタイル・インスティチュート・フォール・ビオテヒノロヒー | Leptin-mediated gene induction |
US6541604B1 (en) | 1996-01-08 | 2003-04-01 | Genentech, Inc. | Leptin receptor having a WSX motif |
US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
US7074397B1 (en) | 1996-01-08 | 2006-07-11 | Genentech, Inc. | Method for enhancing proliferation or differentiation of a cell using ob protein |
US7208572B2 (en) | 1998-08-21 | 2007-04-24 | Albany Medical College | Leptin-related peptides |
US8227408B2 (en) | 2005-09-07 | 2012-07-24 | Neurotez, Inc. | Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology |
US8642543B2 (en) | 2005-09-07 | 2014-02-04 | Neurotez, Inc. | Methods for treating progressive cognitive disorders related to neurofibrillary tangles |
US8716220B2 (en) | 2005-09-07 | 2014-05-06 | Nikolaos Tezapsidis | Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6672157B2 (en) * | 2013-11-26 | 2020-03-25 | ザ チルドレンズ メディカル センター コーポレーション | Compounds for treating obesity and methods of using the same |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996005309A2 (en) * | 1994-08-17 | 1996-02-22 | The Rockefeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
WO1996035787A1 (en) * | 1995-05-08 | 1996-11-14 | Chiron Corporation | Nucleic acids for treating obesity |
WO1997019952A1 (en) * | 1995-11-27 | 1997-06-05 | Millennium Pharmaceuticals, Inc. | The ob receptor and methods of diagnosing and treating weight |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000502569A (en) * | 1996-01-04 | 2000-03-07 | アムジエン・インコーポレーテツド | OB protein receptor and related compositions and related methods |
JP2002514904A (en) * | 1996-06-20 | 2002-05-21 | メルク エンド カンパニー インコーポレーテッド | Gene therapy for obesity |
US5869037A (en) * | 1996-06-26 | 1999-02-09 | Cornell Research Foundation, Inc. | Adenoviral-mediated gene transfer to adipocytes |
-
1997
- 1997-06-20 CA CA002258504A patent/CA2258504A1/en not_active Abandoned
- 1997-06-20 JP JP10503629A patent/JP2000514422A/en active Pending
- 1997-06-20 WO PCT/US1997/012131 patent/WO1997048419A1/en not_active Application Discontinuation
- 1997-06-20 EP EP97932580A patent/EP0921820A4/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996005309A2 (en) * | 1994-08-17 | 1996-02-22 | The Rockefeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
WO1996035787A1 (en) * | 1995-05-08 | 1996-11-14 | Chiron Corporation | Nucleic acids for treating obesity |
WO1997019952A1 (en) * | 1995-11-27 | 1997-06-05 | Millennium Pharmaceuticals, Inc. | The ob receptor and methods of diagnosing and treating weight |
Non-Patent Citations (4)
Title |
---|
BLOOD, 15 November 1995, FLETCHER F.A. et al., "Replacement Gene Therapy Phenotypically Corrects the Fat Deposition Defect in Ob/Ob Mice", page 241a, Abstract 951. * |
PROC. NATL. ACAD. SCI. U.S.A., December 1996, Vol. 93, CHEN G. et al., "Disappearance of Body Fat in Normal Rats Induced by Adenovirus-Mediated Leptin Gene Therapy", pages 14795-14799. * |
PROC. NATL. ACAD. SCI. U.S.A., December 1996, Vol. 93, MUZZIN P. et al., "Correction of Obesity and Diabetes in Genetically Obese Mice by Leptin Gene Therapy", pages 14804-14808. * |
See also references of EP0921820A4 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
US7074397B1 (en) | 1996-01-08 | 2006-07-11 | Genentech, Inc. | Method for enhancing proliferation or differentiation of a cell using ob protein |
US6541604B1 (en) | 1996-01-08 | 2003-04-01 | Genentech, Inc. | Leptin receptor having a WSX motif |
JP2002521496A (en) * | 1998-07-28 | 2002-07-16 | フラームス・インテルウニフェルシタイル・インスティチュート・フォール・ビオテヒノロヒー | Leptin-mediated gene induction |
US7186694B2 (en) | 1998-08-21 | 2007-03-06 | Albany Medical College | Leptin-related peptides |
US6777388B1 (en) | 1998-08-21 | 2004-08-17 | Clf Medical Technology Acceleration Program, Inc. | Leptin-related peptides |
WO2000011173A1 (en) * | 1998-08-21 | 2000-03-02 | Albany Medical College | Leptin-related peptides |
US7208572B2 (en) | 1998-08-21 | 2007-04-24 | Albany Medical College | Leptin-related peptides |
US7786265B2 (en) | 1998-08-21 | 2010-08-31 | Albany Medical College | Isolated antibodies against biologically active leptin-related peptides |
US7790683B2 (en) | 1998-08-21 | 2010-09-07 | Albany Medical College | Leptin-related peptides |
US8022189B2 (en) | 1998-08-21 | 2011-09-20 | Albany Medical College | Isolated antibodies against biologically active leptin-related peptides |
US8067545B2 (en) | 1998-08-21 | 2011-11-29 | Albany Medical College | Isolated antibodies against biologically active leptin-related peptides |
US8227408B2 (en) | 2005-09-07 | 2012-07-24 | Neurotez, Inc. | Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology |
US8642543B2 (en) | 2005-09-07 | 2014-02-04 | Neurotez, Inc. | Methods for treating progressive cognitive disorders related to neurofibrillary tangles |
US8716220B2 (en) | 2005-09-07 | 2014-05-06 | Nikolaos Tezapsidis | Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta |
Also Published As
Publication number | Publication date |
---|---|
EP0921820A1 (en) | 1999-06-16 |
JP2000514422A (en) | 2000-10-31 |
EP0921820A4 (en) | 2003-01-15 |
CA2258504A1 (en) | 1997-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6001816A (en) | Gene therapy for leptin deficiency | |
US6174527B1 (en) | Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism | |
US6608038B2 (en) | Methods and compositions for treatment of diabetes and related conditions via gene therapy | |
JP5616016B2 (en) | Biological pacemaker | |
US7053062B2 (en) | Compositions and methods for inducing gene expression | |
JP2017212995A (en) | Vectors conditionally expressing proteins | |
WO2000040740A2 (en) | Gene therapy to promote angiogenesis | |
KR20210030965A (en) | Gene therapy vectors for treating Danon's disease | |
WO1997048806A1 (en) | Gene therapy for obesity | |
US5700657A (en) | Vectors and vector systems including genes encoding tumor suppressor proteins and producer cells transformed thereby | |
KR20200095462A (en) | Adeno-associated virus composition for restoring HBB gene function and method of use thereof | |
EP0921820A1 (en) | Gene therapy for obesity | |
CA2252470A1 (en) | Treatment of human cancers with an adenovirus vector containing an interferon consensus gene | |
EP0934422B1 (en) | Gene therapy for congestive heart failure | |
US6630346B1 (en) | Gene therapy for obesity | |
JP2002522558A (en) | Adenoviral vectors encoding erythropoietin and their use in gene therapy | |
US20030215423A1 (en) | Gene therapy for obesity | |
US20230101788A1 (en) | Gene therapy | |
JP2002507384A (en) | Method for producing adenovirus vector, vector produced thereby and use thereof | |
JP2003526321A (en) | Treatment of diabetes with synthetic beta cells | |
US20030148952A1 (en) | Methods and materials for the recruitment of endothelial cells | |
KR101835108B1 (en) | Pharmaceutical Composition for Preventing or Treating Diabetes Comprising Recombinant Adenovirus Expressing PREB | |
CA2718347A1 (en) | Gene therapy for congestive heart failure | |
MXPA00005516A (en) | Compositions and methods for inducing gene expression | |
MXPA98009063A (en) | Vector of adenovirus containing an interferon consensus gene for the treatment of cancereshuma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1997932580 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2258504 Country of ref document: CA Ref country code: CA Ref document number: 2258504 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1997932580 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997932580 Country of ref document: EP |